Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily affects motor neurons. While the vast majority of ALS cases occur sporadically, about 5-10% of ALS cases are inherited. ALS patients harboring mutations in the gene that codes for a 43 kD TAR DNA-binding protein (TDP-43) exhibit aggregated proteins within affected motor neurons. Current data suggests that these aggregates contain the TDP-43 protein and this aggregation is connected to disease pathology. Cells have evolved a quality control system called proteostasis, which consists of a suite of molecular chaperones that prevents protein misfolding, maintaining a functional proteome. To examine whether a disruption in proteostasis leads to TDP-43 related neurotoxicity, we have established a C. elegans model that expresses human TDP-43 fused to a yellow fluorescent protein (YFP) under the control of a pan-neuronal promoter. Using well-established behavioral assays, we found that TDP-43 animals have reduced egg laying rates, decreased motility, and lowered chemosensory and mechanosensory detection compared to wild type suggesting defects in neuronal functionality. To assess whether these defects are due to neurodegeneration, we visualized the morphological integrity of specific motor and sensory neurons using fluorescence microscopy. We found that loss of neuronal functionality is not due to observable changes in neuronal structure. To test whether neuronal dysfunction is linked to perturbations in proteostasis, we altered chaperone levels by introducing extra copies of
hsf-1 and a mutant allele of
hsf-1(
sy441) into
tdp-43 trasngenic animals. Data generated from behavioral assays suggest that imbalances in proteostasis contribute to the neuronal dysfunction associated with TDP-43 expression.